Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaIoana Agache, Marek Jutel, Jonathan Corren et al.|Allergy|2020Cited by 406
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaIoana Agache, Marek Jutel, Claudio Rocha et al.|Allergy|2020Cited by 139
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthmaIoana Agache, Marek Jutel, Yang Song et al.|Allergy|2020Cited by 89
GRADE concept paper 2: Concepts for judging certainty on the calibration of prognostic models in a body of validation studiesFarid Foroutan, Alfonso Iorio, Gordon Guyatt et al.|Journal of Clinical Epidemiology|2021Cited by 23